Dr. William E. Haskins has been appointed director of R&D, Bioanalytical Chemistry at Catalent Pharma Solutions. Dr. Haskins reports to Dr. David Rabuka, Catalent Biologics’ Global Head of R&D Chemical Biology, and will join the team first formed by Redwood Bioscience, now a part of Catalent Biologics.
 
He will lead bioanalytical chemistry activities supporting Catalent’s SMARTag technology, a precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs) and other therapeutic bioconjugates. He will be based at the company’s facility in Emeryville, CA.
 
Dr. Haskins joins the company from Genentech, where he led development and analytical characterization of therapeutic ADCs, from late stage research to commercial. He has more than 23 years of basic and translational research experience, including drug and technical development leadership roles in Protein Analytical Chemistry at Genentech, seven years as a Director and Principal Investigator in the University of Texas system, and more than five years of experience with major pharmaceutical, biotechnology and biomarker companies.
 
“Will brings a great deal of experience and knowledge in the fields of ADCs and bioanalytical chemistry to our expanding SMARTag team in Emeryville. He will be a key component to our ongoing efforts to expand and grow our technical platform and analytical offerings,” commented Dr. Rabuka. “We will continue to actively recruit the highest quality personnel for our biologics business as we expand our differentiating technology platforms in this sector.”